Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.
Xia WangLin YangYing ChengPeilin ZhengJingping HuGan HuangZhiguang ZhouPublished in: Journal of diabetes investigation (2018)
The data confirmed that sitagliptin altered the phenotype of T cells and downregulated the expression of T-BET and RORC in LADA patients, and ameliorated glycemic control in LADA patients.
Keyphrases
- glycemic control
- randomized controlled trial
- end stage renal disease
- type diabetes
- newly diagnosed
- ejection fraction
- chronic kidney disease
- open label
- squamous cell carcinoma
- clinical trial
- cardiovascular disease
- study protocol
- prognostic factors
- adipose tissue
- electronic health record
- insulin resistance
- rectal cancer
- double blind